Bilaketaren emaitzak - Stephen J. Schuster

Findu emaitzak
  1. 1
    Bispecific antibodies for the treatment of lymphomas: Promises and challenges

    Bispecific antibodies for the treatment of lymphomas: Promises and challenges nork Stephen J. Schuster

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

    Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy nork Elise A. Chong, Marco Ruella, Stephen J. Schuster

    Argitaratua 2021
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases

    Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases nork Guillermo Garc�a-Manero, Stephen J. Schuster, Herbert Patrick, J. J. Martinez

    Argitaratua 1999
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

    BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte) nork Elise A. Chong, Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era

    Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era nork Sarah Nagle, Kaitlin M. Woo, Stephen J. Schuster, Sunita D. Nasta, Edward A. Stadtmauer, Rosemarie Mick, Jakub Svoboda

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia

    Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia nork Kai‐Uwe Eckardt, Stephen T. Koury, Chorh Chuan Tan, Stephen J. Schuster, Brigitte Kaissling, Peter J. Ratcliffe, Armin Kurtz

    Argitaratua 1993
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET</scp>, <scp>ZUMA</scp>‐1, and <scp>TRANSCEND</scp> trials

    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET<... nork Jason R. Westin, Marie José Kersten, Gilles Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick L. Locke, Charalambos Andreadis

    Argitaratua 2021
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study

    Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study nork Anthony R. Mato, Colleen Timlin, Chaitra S. Ujjani, Alan P Skarbnik, Christina Howlett, Rahul Banerjee, Chadi Nabhan, Stephen J. Schuster

    Argitaratua 2017
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial nork Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch, Vadim Romanov, Frederick L. Locke, David G. Maloney

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial nork Richard T. Maziarz, Stephen J. Schuster, Vadim Romanov, Elisha S. Rusch, Junlong Li, James Signorovitch, David G. Maloney, Frederick L. Locke

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Durable complete responses from therapy with combined epratuzumab and rituximab

    Durable complete responses from therapy with combined epratuzumab and rituximab nork John P. Leonard, Stephen J. Schuster, Christos Emmanouilides, Félix Couture, Nick Teoh, William A. Wegener, Morton Coleman, David M. Goldenberg

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas

    Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas nork Tahamtan Ahmadi, Elise A. Chong, Amanda Gordon, Nicole A. Aqui, Sunita D. Nasta, Jakub Svoboda, Anthony R. Mato, Stephen J. Schuster

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

    Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas nork Elise A. Chong, Tahamtan Ahmadi, Nicole A. Aqui, Jakub Svoboda, Sunita D. Nasta, Anthony R. Mato, Kristy M. Walsh, Stephen J. Schuster

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

    PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR nork Elise A. Chong, J. Joseph Melenhorst, Simon F. Lacey, David E Ambrose, Vanessa Gonzalez, Bruce L. Levine, Carl H. June, Stephen J. Schuster

    Argitaratua 2016
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  15. 15
    High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic Transplantation

    High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic Transplantation nork Elisabeth A. Hagen, H Stern, David Porter, Kathleen M. Duffy, Karen Foley, Selina M. Luger, Stephen J. Schuster, Edward A. Stadtmauer, Mindy G. Schuster

    Argitaratua 2003
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy nork Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster

    Argitaratua 2021
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1

    REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 nork Donald E. Tsai, Christine Hardy, John E. Tomaszewski, Robert M. Kotloff, Kimberly M. Oltoff, Bradley G. Somer, Stephen J. Schuster, David Porter, Kathleen T. Montone, Edward A. Stadtmauer

    Argitaratua 2001
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) nork Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, André Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

    Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma nork Rebecca L. Olin, Dan T. Vogl, David Porter, Selina M. Luger, Stephen J. Schuster, Donald E. Tsai, Don L. Siegel, Richard J. Cook, Patricia Mangan, K. Cunningham, Edward A. Stadtmauer

    Argitaratua 2008
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

    Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results nork Franck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, Marie-Odile Petillon, Morton Coleman, Stephen J. Schuster, Martin J.S. Dyer, Heather Horne, Nick Teoh, William A. Wegener, David M. Goldenberg

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: